var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?d387e539c1f2d34f09a9afbac8032280"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })();
INCYUS
Open
Back To Top
Last Updated: Jan 17, 2020 10:53 a.m. EST Real time quote

$ 80.11

-0.51 -0.63%
Health Care/Life Sciences 0.25%
Previous Close
$80.62
Advanced Charting
  • $
  • %
  • Vol
Advanced Charting
19.87% vs Avg.
Volume: 275.6K 65 Day Avg. - 1.4M
Open: 80.98
Last: 80.11
80.11 Day Low/High 81.11
Day Range
72.00 52 Week Low/High 96.79

Your Watchlist

Customize MarketWatch

Have Watchlists? Log in to see them here or sign up to get started.

Symbol
Company
Price
Chg/Chg %
No Items in Watchlist

There are currently no items in this Watchlist.

No Saved Watchlists

Create a list of the investments you want to track.

Uh oh

Something went wrong while loading Watchlist.

Recently Viewed Tickers

No Recent Tickers

7073彩票注册Visit a quote page and your recently viewed tickers will be displayed here.

Key Data

  • Open $80.98
  • Day Range 80.11 - 81.11
  • 52 Week Range 72.00 - 96.79
  • Market Cap $17.37B
  • Shares Outstanding 215.07M
  • Public Float 213.64M
  • Beta 1.38
  • Rev. per Employee $1.38M
  • P/E Ratio 43.18
  • EPS $1.86
  • Yield n/a
  • Dividend n/a
  • Ex-Dividend Date n/a
  • Short Interest 3.95M 12/31/19
  • % of Float Shorted 1.85%
  • Average Volume 1.39M

Performance

5 Day
  • 4.76%
1 Month
  • -11.09%
3 Month
  • 3.02%
YTD
  • -8.26%
1 Year
  • 2.16%

Recent News

  • MarketWatch
  • WSJ

Democrats Called for Cuts to Drug Prices at the Debate. The Pharma Industry Says It’s Trying.

7073彩票注册Pharmaceutical executives at the J.P. Morgan Healthcare conference say the industry can fixed pricing problems on its own.

Read full story

Dow logs worst day in 4 weeks, amid rising Middle East tensions and weak U.S. factory data

Incyte stock price target cut to $74 from $85 at BMO Research

Oil Is Surging, 7073彩票注册 Is Up, and the Dow Is Dropping After U.S. Airstrike

Shares of oil producers are up, but stock in airlines is falling. Prices of Treasury debt, a haven investment, have risen.

Incyte Stock Is Tanking After a Disappointing Study. Analysts Are Mixed on How Bad the News Really Is.

As shares of Incyte fell about 10.8% in premarket trading on Friday, analysts were divided on whether the trial results were a serious setback for the company.

Incyte stock slammed after study fails to hit goal

7073彩票注册Incyte Corp. shares fell more than 12% in after-hours trading Thursday after the company revealed that a phase-3 study of a drug failed to reach its goal. Incyte said that a study seeking to pair itacitinib with corticosteroids to treat a form of graft-versus-host disease, which can strike patients who have had a blood-marrow transplant. The study showed that the treatment was not significantly better than a placebo statistically, the primary endpoint of the study. The key secondary endpoint also was not reached. "The result of this study is disappointing," Incyte Chief Medical Officer Steven Stein said in Thursday's announcement. Incyte's stock closed with a 1.6% decline at $85.97, then plunged to lower than $76 in the extended session after the news was released. Shares have gained 35.3% in the past 12 months, as the S&P 500 index has increased 28.7%.

The 3 Best-Performing Health Care 7073彩票注册 of 2019 So Far

7073彩票注册7073彩票注册 to be thankful for.

The Dow Is Rising Because China Might Finally Target the Theft of Intellectual Property

The market is also getting a lift from a spare of merger activity on Monday. TD Ameritrade is being bought by Charles Schwab, LVMH is buying Tiffany, and Novartis is acquiring the Medicines Co.

Read full story

Sales winners in the third quarter include Netflix, Autodesk and PayPal

Constellation shares soar 95% after promising data from rare disease trial

7073彩票注册Shares of Constellation Pharmaceuticals Inc. jumped 95% after the biopharmaceutical company reported promising data from a mid-stage clinical trial for myelofibrosis. In this trial, it was used in combination with Incyte Corp.'s Jakafi, the first treatment approved by the U.S. Food and Drug Administration for the rare bone marrow disorder. The company plans to test the therapy as a first-line treatment and expects to launch a randomized late-stage clinical trial for CPI-0610 next year. Constellation stock has gone up 684% year-to-date, while the S&P 500 has risen 23%.

The Dow Is Up a Few Points Because Hope on Trade Isn’t the Same as Rocket Fuel

The Dow Jones Industrial Average was close to flat as markets hugged close to the break-even line after Monday’s record close for the S&P 500 and President Donald Trump reported trade talk progress.

Incyte reports positive results in late-stage trial of treatment for GVHD

Incyte rerpots positive results in trial of treatment for GVHD

Incyte shares up 1.2% premarket

Amgen, Merck and Others Highlight Cancer-Drug Developments in Barcelona

The 3 Best Health-Care 7073彩票注册 This Month. And the Worst

Read full story

A Big Cancer Conference Starts Tomorrow. What Means for Merck, Bristol-Myers Squibb

Incyte upgraded to outperform from perform at Oppenheimer

Incyte stock price target raised to $100 from $85 at Oppenheimer

Read full story

3 stocks that can make you money despite a trade war or recession

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

on The Wall Street Journal

Recent News

  • Other News
  • Press Releases

7073彩票注册MorphoSys and Incyte team up to advance tafasitamab in $2B deal

on Seeking Alpha

7073彩票注册Investors unmoved with Morphosys' tafasitamab deal, shares down 8%

on Seeking Alpha

Incyte (INCY) closed at $76.53 in the latest trading session, marking a -0.79% move from the prior day.

on Zacks.com

7073彩票注册Biotech Bonanza: 2020 Outlook In An Election Year

on Seeking Alpha

The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.

on Zacks.com

7073彩票注册A low-key week for the biotech sector, with a few pipeline and regulatory updates.

on Zacks.com

EMA accepts Incyte's pemigatinib application for cholangiocarcinoma

on Seeking Alpha

7073彩票注册Black Diamond Therapeutics Begins IPO Effort

on Seeking Alpha

Companies In The News Are: CANF, LW, INCY, NOVN

on Zacks.com

Incyte: Looking More Appealing, Yet Pipeline Conversion Is Required

on Seeking Alpha

Stock Market Today: Is the Rally Ruined?; Tesla’s New Record

on InvestorPlace.com

Incyte News: INCY Stock Tumbles 10% on Experimental Drug Study Failure

on InvestorPlace.com

7073彩票注册Incyte's pain is Equillium's gain, up 12%

on Seeking Alpha

7073彩票注册OCUL, ACOR, INCY and DPW among midday movers

on Seeking Alpha

7073彩票注册Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.

on Zacks.com

7073彩票注册man likes Humana in premarket analyst action

on Seeking Alpha

Incyte's itacitinib flunks GvHD study; shares down 10% after hours

on Seeking Alpha

Evercore sees 12% upside in Baxter in premarket analyst action

on Seeking Alpha

Incyte Corporation: Wait And Watch

on Seeking Alpha

In the latest trading session, Incyte (INCY) closed at $88.39, marking a -0.44% move from the previous day.

on Zacks.com

Serine Threonine Protein Kinase Pim 3, Pipeline Review, H2 2019 - Incyte Corp, Jasco Pharmaceuticals, Novartic AG & Yakult Honsha Co. Ltd. - ResearchAndMarkets.com

7073彩票注册Serine Threonine Protein Kinase Pim 3, Pipeline Review, H2 2019 - Incyte Corp, Jasco Pharmaceuticals, Novartic AG & Yakult Honsha Co. Ltd. - ResearchAndMarkets.com

on BusinessWire - BZX

Hodgkin Lymphoma Drug Market 2020 To Expand At A CAGR Of 14.5% By Affimed GmbH, Aeterna Zentaris Inc. Actinium Pharmaceuticals, Inc., 4SC AG, F. Hoffmann-La Roche Ltd

Hodgkin Lymphoma Drug Market 2020 To Expand At A CAGR Of 14.5% By Affimed GmbH, Aeterna Zentaris Inc. Actinium Pharmaceuticals, Inc., 4SC AG, F. Hoffmann-La Roche Ltd

on The Express Wire

Bromodomain Containing Protein 2 Market Share by Top 7 Players | Covered Major Segments, Regions and Key Drivers Outlook 2026

Bromodomain Containing Protein 2 Market Share by Top 7 Players | Covered Major Segments, Regions and Key Drivers Outlook 2026

on Market Prediction

Tumor Necrosis Factor Receptor Superfamily Member 18 Market Trends, Analysis, Statistics and Forecast 2019 to 2026

Tumor Necrosis Factor Receptor Superfamily Member 18 Market Trends, Analysis, Statistics and Forecast 2019 to 2026

on Market Prediction

Tumor Necrosis Factor Receptor Superfamily Member 4 Market Trends, Analysis, Statistics and Forecast 2019 to 2026

Tumor Necrosis Factor Receptor Superfamily Member 4 Market Trends, Analysis, Statistics and Forecast 2019 to 2026

on Global QYResearch

Psoriasis Therapeutics Market Industry Analysis by Regions, Trends & Forecast 2026|Johnson & Johnson, Novartis AG, Merck & Co. Inc.

Psoriasis Therapeutics Market Industry Analysis by Regions, Trends & Forecast 2026|Johnson & Johnson, Novartis AG, Merck & Co. Inc.

on The Express Wire

Nasdaq 100 Movers: ALXN, AAL

Nasdaq 100 Movers: ALXN, AAL

on MarketNewsVideo.com

MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab

MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab

on ACCESSWIRE

Indolent Lymphoma Treatment Market Detailed Analysis Of The Market Structure, Market Trends Along With Growth Forecast To 2025

Indolent Lymphoma Treatment Market Detailed Analysis Of The Market Structure, Market Trends Along With Growth Forecast To 2025

on The Express Wire

MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

7073彩票注册MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

on ACCESSWIRE

DGAP-News: MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

DGAP-News: MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

on EQS Group AG

Waldenstrom Macroglobulinemia Therapeutics Market to Witness Study Growth through 2019-2026

7073彩票注册Waldenstrom Macroglobulinemia Therapeutics Market to Witness Study Growth through 2019-2026

on Market Prediction

MacroGenics Outlines Corporate Priorities for 2020

MacroGenics Outlines Corporate Priorities for 2020

on GlobeNewswire

Bromodomain Testis Specific Protein Market By Trends, Growth Drivers, Market Dynamics, Business Strategies with Future Prospects 2019-2026

7073彩票注册Bromodomain Testis Specific Protein Market By Trends, Growth Drivers, Market Dynamics, Business Strategies with Future Prospects 2019-2026

on Global QYResearch

Essential Thrombocythemia Drug Market 2019 Size, Share, Current trends, Competitive Analysis and Forecast to 2026

Essential Thrombocythemia Drug Market 2019 Size, Share, Current trends, Competitive Analysis and Forecast to 2026

on Market Prediction

Thrombocythaemia Myelofibrosis Treatment Market Trends, Analysis, Statistics and Forecast 2019 to 2026

7073彩票注册Thrombocythaemia Myelofibrosis Treatment Market Trends, Analysis, Statistics and Forecast 2019 to 2026

on Market Prediction

Immune Checkpoint Inhibitors Market 2019 Share, Trends, Segmentation and Forecast by 2025

Immune Checkpoint Inhibitors Market 2019 Share, Trends, Segmentation and Forecast by 2025

on Brandessence Market Research

Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma

7073彩票注册Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma

on BusinessWire - BZX

Janus Kinase (JAK) Inhibitors Market expected to succeed CAGR of 18.05% until 2023, Current business standing in Pharmaceuticals, Biotechnology & Life Sciences,Pharmaceuticals Sector .

7073彩票注册Janus Kinase (JAK) Inhibitors Market expected to succeed CAGR of 18.05% until 2023, Current business standing in Pharmaceuticals, Biotechnology & Life Sciences,Pharmaceuticals Sector .

on The Express Wire

Nasdaq 100 Movers: SGEN, GOOGL

Nasdaq 100 Movers: SGEN, GOOGL

on MarketNewsVideo.com

Incyte Corp.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. (See Full Profile)

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 19 Full Ratings

Competitors

Name Chg % Market Cap
Eli Lilly & Co. -0.34% $135.79B
Ionis Pharmaceuticals Inc. -1.05% $8.65B
Ligand Pharmaceuticals Inc. -0.57% $1.63B
Pfizer Inc. -0.25% $224.74B
Novartis AG ADR 0.50% $217.58B
Competitor Data Provided By
689彩票邀请码 7072彩票开户 7073彩票注册 963彩票开户 7073彩票网址 7073彩票地址 7073彩票登录 66顺彩票app 8炫彩彩票app 677彩票开户